However, PAPP-A has also been proposed to be a tumor suppressor following the discovery that it is epigenetically silenced in breast cancer precursor lesions [29], and survival analysis in this study, using publicly available breast cancer gene expression datasets, showed that reduced PAPPA is associated with worse outcomes in ILC. This evidence concerns the gene PAPPA and breast carcinoma.